Carregant...
Use of anti-TNF drug levels to optimise patient management
Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab pegol and golimumab, have been proven to be effective for the treatment of patients with Crohn's disease and ulcerative colitis. However, 10%–30% of patients with inflammatory bowel disease (IBD) show no i...
Guardat en:
| Publicat a: | Frontline Gastroenterol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5369499/ https://ncbi.nlm.nih.gov/pubmed/28839870 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/flgastro-2016-100685 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|